Trading in Rigel halted ahead of expected FDA OK for Tavalisse for immune thrombocytopenia; shares up 10%

|About: Rigel Pharmaceuticals,... (RIGL)|By:, SA News Editor

Nasdaq has suspended trading in Rigel Pharmaceuticals (RIGL +10.2%) based on abnormal volatility. Today is the FDA's action date for its review of the company's marketing application seeking approval for Tavalisse (fostamatinib) for the treatment of chronic or persistent immune thrombocytopenia (low blood platelets).

Previously: No Ad Com review for Rigel's marketing application for thrombocytopenia med fostamatinib; shares ahead 14% premarket (Oct. 2, 2017)

Update: The company reported that it has received the FDA nod.

Subscribe for full text news in your inbox